Compare EXPI & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXPI | GERN |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 808.3M |
| IPO Year | 2010 | N/A |
| Metric | EXPI | GERN |
|---|---|---|
| Price | $6.76 | $1.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $9.75 | $2.17 |
| AVG Volume (30 Days) | 1.0M | ★ 13.9M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,147,681.00 | N/A |
| Revenue This Year | $6.26 | $26.91 |
| Revenue Next Year | $5.50 | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 220.39 | N/A |
| 52 Week Low | $5.66 | $1.04 |
| 52 Week High | $12.23 | $2.01 |
| Indicator | EXPI | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 34.40 |
| Support Level | $5.68 | $1.22 |
| Resistance Level | $6.87 | $1.29 |
| Average True Range (ATR) | 0.23 | 0.06 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 81.56 | 21.15 |
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.